SCHEMBL1995471

SCHEMBL1995471

CCC(=O)Oc1c(F)c(F)cc(F)c1F

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 2/20 0.40
HIF1A Q16665 2/20 0.40
RECQL P46063 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA4 P22748 2/20 0.39
MAPT P10636 2/20 0.39
HTT P42858 2/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
ACHE P22303 3/20 0.39
ALOX15 P16050 1/20 0.39
ELANE P08246 1/20 0.37
CES2 O00748 1/20 0.37
CES1 P23141 1/20 0.37
ACLY P53396 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15763915 0.85 MAPT (0.43) KMT2ACA1CA2CA4MAPT
SCHEMBL1998865 0.84 ESR1 (0.42) ESR1HIF1ARECQLKMT2ASMN1; SMN2
SCHEMBL2000685 0.84 ALOX15 (0.41) KMT2ACA1CA2CA4MAPT
SCHEMBL1401782 0.82 HIF1A (0.41) ESR1HIF1ARECQLKMT2ASMN1; SMN2
SCHEMBL2000768 0.82 KMT2A (0.47) ESR1HIF1ARECQLKMT2ASMN1; SMN2
SCHEMBL10180980 0.82 KMT2A (0.39) ESR1HIF1ARECQLKMT2ASMN1; SMN2
SCHEMBL17373963 0.82 VCAM1 (0.38) KMT2ACA1CA2CA4MAPT
SCHEMBL17337902 0.82 KMT2A (0.40) KMT2ACA1CA2CA4MAPT
SCHEMBL1998098 0.81 KMT2A (0.44) RECQLKMT2ASMN1; SMN2KDM4EALOX15
Fluoride SCHEMBL27712387 0.80 HIF1A (0.39) ESR1HIF1ARECQLKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8952083-B2 Fluorocopolymer composition and its production process ASAHI GLASS COMPANY, LIMITED (JP) 2015-02-10 US claimed
EP-4559901-A1 RADIOLABELED ACTIVATED ESTER AND PRECURSOR THEREOF Institute of Science Tokyo (JP) 2025-05-28 EP disclosed
US-20230364251-A1 METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES CIDARA THERAPEUTICS, INC. 2023-11-16 US disclosed
US-11793895-B2 Residualizing linkers and uses thereof CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION 2023-10-24 US disclosed
CN-116897054-A anti-HER 2 immunoconjugates and uses thereof 博尔特生物治疗药物有限公司 2023-10-17 CN disclosed
CN-116744978-A anti-HER 2 immunoconjugates and uses thereof 博尔特生物治疗药物有限公司 2023-09-12 CN disclosed
CN-116723866-A anti-PD-L1 immunoconjugates and uses thereof 博尔特生物治疗药物有限公司 2023-09-08 CN disclosed
US-20230273194-A1 NON-INVASIVE METHOD FOR DETECTION OF ENZYME ACTIVITY IN VIVO, SUBSTRATES AND A DEVICE THEREFORE ETH Zürich (CH) 2023-08-31 US disclosed
US-20230273194-A1 NON-INVASIVE METHOD FOR DETECTION OF ENZYME ACTIVITY IN VIVO, SUBSTRATES AND A DEVICE THEREFORE ETH Zürich (CH) 2023-08-31 US disclosed
CN-116635084-A anti-CEA immunoconjugates and uses thereof 博尔特生物治疗药物有限公司 2023-08-22 CN disclosed
US-20170355731-A1 AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION 2017-12-14 US disclosed
WO-2017191579-A1 AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE NOVARTIS AG (CH) 2017-11-09 WO disclosed
US-9751953-B2 Antibodies to risperidone haptens and use thereof JANSSEN PHARMACEUTICA NV (BE) 2017-09-05 US disclosed
WO-2015073575-A2 RESIDUALIZING LINKERS AND USES THEREOF CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION (CA) 2015-05-21 WO disclosed
US-8952083-B2 Fluorocopolymer composition and its production process ASAHI GLASS COMPANY, LIMITED (JP) 2015-02-10 US disclosed
CN-102186921-B Fluorine-containing copolymer composition and process for production thereof ASAHI GLASS CO LTD 2014-01-15 CN disclosed
EP-2338935-B1 FLUORINE-CONTAINING COPOLYMER COMPOSITION AND PROCESS FOR PRODUCTION THEREOF ASAHI GLASS CO LTD (JP) 2012-12-12 EP disclosed
CN-102186921-A Fluorine-containing copolymer composition and process for production thereof ASAHI GLASS CO LTD 2011-09-14 CN disclosed
US-20110172336-A1 FLUOROCOPOLYMER COMPOSITION AND ITS PRODUCTION PROCESS ASAHI GLASS COMPANY, LIMITED (JP) 2011-07-14 US disclosed
EP-2338935-A1 FLUORINE-CONTAINING COPOLYMER COMPOSITION AND PROCESS FOR PRODUCTION THEREOF ASAHI GLASS COMPANY, LIMITED (JP) 2011-06-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355731-A1 AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE RNGTT, RNASE1, RNMT ESR1 4726/4885HIF1A 2275/4885RECQL 1218/4885
US-11793895-B2 Residualizing linkers and uses thereof CD44, CD47, MTCL3 ESR1 3474/4885HIF1A 3834/4885RECQL 3973/4885
US-20230364251-A1 METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES DNPEP, NPEPPS, DHFR ESR1 4015/4885HIF1A 2560/4885RECQL 3557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.